Search results for "Cancer Research"

showing 10 items of 5684 documents

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

2018

Abstract Background: PIK3CA, a gene that encodes the α-isoform of the catalytic subunit of Class I PI3K (PI3Kα), is frequently mutated or amplified in solid tumors. Taselisib is an oral, potent, selective inhibitor of Class I PI3Kα, γ, and δ isoforms with enhanced activity against PIK3CA-mutated cancer models. Preclinical and clinical data demonstrated that single-agent taselisib has activity in multiple PIK3CA-mutated tumor types. Methods: This open-label phase I study (Cohort X of PMT4979g; NCT01296555) enrolled patients (pts) with PIK3CA-mutated tumors who had progressed after, or failed to respond to, at least one prior treatment regimen and were not candidates for regimens known to pro…

0301 basic medicineCervical cancerCancer Researchmedicine.medical_specialtybusiness.industryEndometrial cancerNot Otherwise SpecifiedCancermedicine.diseaseGastroenterologyHead and neck squamous-cell carcinoma03 medical and health sciencesRegimen030104 developmental biologyOncologyTolerabilityResponse Evaluation Criteria in Solid TumorsInternal medicinemedicinebusinessCancer Research
researchProduct

Uncovering Metabolic Effects of Anti-angiogenic Therapy in Tumors by Induced Metabolic Bioluminescence Imaging

2016

Induced metabolic bioluminescence imaging (imBI) is an imaging technique which enables detection of various metabolites associated with glycolysis in tumor sections. Signals captured by imBI can be used to chart the topographic distribution of lactate, glucose, pyruvate, and ATP and quantify their absolute amount. ImBi can enable us to perform metabolic classification of tumors as well as to detect metabolic changes in the glycolytic pathway associated with certain therapies, such as anti-angiogenic drugs.

0301 basic medicineChemistryAngiogenesisAnti angiogenic03 medical and health sciences030104 developmental biology0302 clinical medicineAbsolute amount030220 oncology & carcinogenesisMetabolic effectsCancer researchBioluminescence imagingBioluminescenceDistribution (pharmacology)Glycolysis
researchProduct

2020

PIK3CA-related overgrowth spectrum is caused by mosaicism mutations in the PIK3CA gene. These mutations, which are also observed in various types of cancer, lead to a constitutive activation of the PI3K/AKT/mTOR pathway, increasing cell proliferation. Heat shock transcription factor 1 (HSF1) is the major stress-responsive transcription factor. Recent findings indicate that AKT phosphorylates and activates HSF1 independently of heat-shock in breast cancer cells. Here, we aimed to investigate the role of HSF1 in PIK3CA-related overgrowth spectrum. We observed a higher rate of proliferation and increased phosphorylation of AKT and p70S6K in mutant fibroblasts than in control cells. We also fou…

0301 basic medicineChemistryCell growthfungiMutantBiophysicsCell BiologyBiochemistry3. Good healthHeat shock factor03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisCancer researchPhosphorylationHSF1Molecular BiologyTranscription factorProtein kinase BPI3K/AKT/mTOR pathwayBiochemical and Biophysical Research Communications
researchProduct

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines

2016

Intranodal immunization with antigen-encoding naked mRNA has proven to be an efficacious and safe approach to induce antitumor immunity. Thanks to its unique characteristics, mRNA can act not only as a source for antigen but also as an adjuvant for activation of the immune system. The search for additional adjuvants that can be combined with mRNA to further improve the potency of the immunization revealed Fms-like tyrosine kinase 3 (FLT3) ligand as a potent candidate. Systemic administration of the dendritic cell-activating FLT3 ligand prior to or along with mRNA immunization-enhanced priming and expansion of antigen-specific CD8(+) T cells in lymphoid organs, T-cell homing into melanoma tu…

0301 basic medicineChemistrymedicine.medical_treatmentPriming (immunology)chemical and pharmacologic phenomenaImmunotherapyDendritic cellbiochemical phenomena metabolism and nutrition03 medical and health sciences030104 developmental biologyImmune systemAntigenSystemic administrationmedicineCancer researchbacteriaAdjuvantCD8
researchProduct

NFATc1 releases BCL6-dependent repression of CCR2 agonist expression in peritoneal macrophages fromSaccharomyces cerevisiaeinfected mice

2016

The link between the extensive usage of calcineurin (CN) inhibitors cyclosporin A and tacrolimus (FK506) in transplantation medicine and the increasing rate of opportunistic infections within this segment of patients is alarming. Currently, how peritoneal infections are favored by these drugs, which impair the activity of several signaling pathways including the Ca(++) /CN/NFAT, Ca(++) /CN/cofilin, Ca(++) /CN/BAD, and NF-κB networks, is unknown. Here, we show that Saccharomyces cerevisiae infection of peritoneal resident macrophages triggers the transient nuclear translocation of NFATc1β isoforms, resulting in a coordinated, CN-dependent induction of the Ccl2, Ccl7, and Ccl12 genes, all enc…

0301 basic medicineChemokineReceptors CCR2Calcineurin InhibitorsImmunologySaccharomyces cerevisiaeOpportunistic InfectionsCCL7MonocytesMice03 medical and health sciences0302 clinical medicineCyclosporin aAnimalsProtein IsoformsImmunology and AllergyChemokine CCL7Promoter Regions GeneticCCL12Transcription factorChemokine CCL2NFATC Transcription FactorsbiologyCalcineurinNF-kappa BNFATNFATC Transcription FactorsMonocyte Chemoattractant Proteins3. Good healthCalcineurinProtein Transport030104 developmental biology030220 oncology & carcinogenesisMacrophages PeritonealProto-Oncogene Proteins c-bcl-6biology.proteinCancer researchEuropean Journal of Immunology
researchProduct

Eosinophil depletion suppresses radiation-induced small intestinal fibrosis.

2017

Radiation-induced intestinal fibrosis (RIF) is a serious complication after abdominal radiotherapy for pelvic tumor or peritoneal metastasis. Herein, we show that RIF is mediated by eosinophil interactions with α-smooth muscle actin-positive (α-SMA+) stromal cells. Abdominal irradiation caused RIF especially in the submucosa (SM) of the small intestine, which was associated with the excessive accumulation of eosinophils in both human and mouse. Eosinophil-deficient mice showed markedly ameliorated RIF, suggesting the importance of eosinophils. After abdominal irradiation, chronic crypt cell death caused elevation of extracellular adenosine triphosphate, which in turn activated expression of…

0301 basic medicineChemokineStromal cellCCR303 medical and health sciencesChemokine receptorMiceIntestine SmallmedicineAnimalsIntestinal MucosaReceptorCCL11biologyChemistryGeneral Medicinerespiratory systemEosinophilFibrosisSmall intestineEosinophilsDisease Models AnimalRadiation Injuries Experimental030104 developmental biologymedicine.anatomical_structurebiology.proteinCancer researchScience translational medicine
researchProduct

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct

2018

Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could...

0301 basic medicineChemotherapybiologyColorectal cancerMechanism (biology)business.industrymedicine.medical_treatmentImmunologyImmunotherapymedicine.diseaseImmune checkpoint3. Good healthBlockade03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisPD-L1medicineCancer researchbiology.proteinImmunology and AllergyCytotoxic T cellbusinessOncoImmunology
researchProduct

A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification

1999

N-myc gene amplification and/or loss of heterozygosity of chromosome 1 (LOH lp) are important criteria for prognosis and progression in human neuroblastoma (NB). Despite the high incidence of alterations of the p53 gene in human cancers, very few p53 mutations have been reported in NB. The objective of our study was to search for p53 mutations in NB and their correlation with N-myc amplification and clinical or pathologic parameters. We analyzed 14 selected cases of NB from the Spanish Protocol N-II-92. We found a missense mutation in codon 248 CGG to GGG (Arg/Gly) in one case of stage 4 NB with no N-myc amplification. Our results confirm the low incidence of p53 gene mutation in neuroblas…

0301 basic medicineChromosomeBiologyGene mutationmedicine.diseaseMolecular biologyPathology and Forensic MedicineLoss of heterozygosity03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisNeuroblastomaGene duplicationmedicineCancer researchMissense mutationSurgeryAnatomyGeneN-MycInternational Journal of Surgical Pathology
researchProduct

A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

2015

Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegrada…

0301 basic medicineChronic lymphocytic leukemiaxenograft modelchronic lymphocytic leukemia; immune targeted nanoparticles; treatment; xenograft model; Electrical and Electronic Engineering; Materials Science (all)Nanotechnology03 medical and health sciencesTherapeutic approach0302 clinical medicinehemic and lymphatic diseasesmedicineGeneral Materials ScienceElectrical and Electronic EngineeringCytotoxicityCD20immune targeted nanoparticletreatmentChlorambucilbiologybusiness.industryTherapeutic effectHydroxychloroquineCondensed Matter Physicsmedicine.diseaseAtomic and Molecular Physics and OpticsLeukemia030104 developmental biology030220 oncology & carcinogenesisimmune targeted nanoparticlesCancer researchbiology.proteinchronic lymphocytic leukemiaMaterials Science (all)businessmedicine.drugNano Research
researchProduct